Paclitaxel, carboplatino ed ipertermia contro cellule di osteosarcoma

Stampa

Paclitaxel, carboplatino ed ipertermia contro cellule di osteosarcoma

 foto di provetteUna interessante esperienza pubblicata su rivista medica internazionale circa il potenziamento di paclitaxel e carboplatino contro cellule di osteosarcoma in presenza di ipertermia.

 

 

 

 

Dr. Carlo Pastore


Asian Pac J Cancer Prev. 2012;13(1):81-5.

Induction of apoptosis by a combination of paclitaxel and carboplatin in the presence of hyperthermia.

Huang T, Gong WH, Li XC, Zou CP, Jiang GJ, Li XH, Feng DP.

Source

Department of Orthopedics, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

Abstract

PURPOSE:

To study enhancing effects of paclitaxel in the thermochemotherapy of osteosarcoma cell lines and related mechanisms.

MATERIALS AND METHODS:

Paclitaxel and carboplatin were used alone or jointly on OS732 cell lines in the presence of hyperthermia. Inhibition of proliferation was measured by MTT assay and cellular changes were assessed with inverted phase contrast and fluorescence microscopy. Apoptosis was analyzed with flow cytometry (FCM) and Fas expression by immunocytochemistry.

RESULTS:

At 43 degrees C, one hour after the application of 10 ?g/ml paclitaxel and 5 ?g/ml carboplatin on OS732 cells jointly, the survival rate was 15.8% which was significantly lower than with 10 ?g/ml paclitaxel (45.8%) and 5 ?g/ml carboplatin (47.7%) respectively (P<0.01). Moreover, changes of morphology and apoptotic rates indicated that the apoptosis-inducing effect of combined application was also much enhanced, as evident also regarding Fas expression.

CONCLUSION:

Paclitaxel is conducive to thermochemotherapy of osteosarcoma cell lines, possibly accomplished by up-regulation of Fas expression with induction of apoptosis.